Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Moderate to Very Severe Chronic Obstructive Pulmonary Disease”

41 trials

Showing 20 of 41 results

Large-scale testing (Phase 3)Study completedNCT02454959
What this trial is testing

Crossover Study to Assess the Efficacy of PT003 With and Without a Valved Holding Chamber in Subjects With Moderate to Severe COPD

Who this might be right for
COPD
Pearl Therapeutics, Inc. 80
Not applicableStudy completedNCT04168775
What this trial is testing

Peak Inspiratory Flow Rates in Patients With COPD

Who this might be right for
COPD
University of North Carolina, Chapel Hill 80
Early research (Phase 1)Study completedNCT03906045
What this trial is testing

A Scintigraphy Study of PT010 in COPD Patients

Who this might be right for
Chronic Obstructive Pulmonary Disease
AstraZeneca 18
Large-scale testing (Phase 3)Study completedNCT02343458
What this trial is testing

Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD

Who this might be right for
Chronic Obstructive Pulmonary Disease
Pearl Therapeutics, Inc. 1,756
Large-scale testing (Phase 3)Not Yet RecruitingNCT07780656
What this trial is testing

Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-2)

Who this might be right for
Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline 624
Testing effectiveness (Phase 2)WithdrawnNCT01043601
What this trial is testing

Efficacy and Safety of Two Doses of Formoterol Fumarate MDI (PT005) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD), Compared to Foradil® Aerolizer® as an Active Control

Who this might be right for
COPD
Pearl Therapeutics, Inc.
Post-approval studies (Phase 4)Study completedNCT03964207
What this trial is testing

A Study on Whether Patients Prefer the Spiriva® Respimat® or the Spiriva® Handihaler® for Treating Their Chronic Obstructive Pulmonary Disease (COPD)

Who this might be right for
Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim 72
Large-scale testing (Phase 3)Study completedNCT02347085
What this trial is testing

24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003 and Placebo MDI

Who this might be right for
COPD
Pearl Therapeutics, Inc. 43
Testing effectiveness (Phase 2)Study completedNCT01085045
What this trial is testing

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PT001, PT003, and PT005 Following Chronic Dosing (7 Days) in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

Who this might be right for
Chronic Obstructive Pulmonary Disease
Pearl Therapeutics, Inc. 118
Large-scale testing (Phase 3)Looking for participantsNCT06878261
What this trial is testing

Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)

Who this might be right for
Chronic Obstructive Pulmonary Disease (COPD)
AstraZeneca 990
Post-approval studies (Phase 4)UnknownNCT02924870
What this trial is testing

Long-term Effect of an Health Education Program on Daily Physical Activity in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

Who this might be right for
Chronic Obstructive Pulmonary Disease
Hospital Universitario La Paz 128
Large-scale testing (Phase 3)WithdrawnNCT03081247
What this trial is testing

To Assess the Efficacy and Safety of PT010 Compared to PT009 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

Who this might be right for
Chronic Obstructive Pulmonary Disease
Pearl Therapeutics, Inc.
Large-scale testing (Phase 3)Study completedNCT02257385
What this trial is testing

Comparative Study of Umeclidinium/Vilanterol (UMEC/VI) in a Fixed Dose Combination With Indacaterol Plus Tiotropium

Who this might be right for
Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline 967
Large-scale testing (Phase 3)Looking for participantsNCT07780669
What this trial is testing

Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-1)

Who this might be right for
Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline 624
Large-scale testing (Phase 3)Study completedNCT01854658
What this trial is testing

Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 2)

Who this might be right for
Chronic Obstructive Pulmonary Disease (COPD)
Pearl Therapeutics, Inc. 1,615
Large-scale testing (Phase 3)Looking for participantsNCT06883305
What this trial is testing

Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)

Who this might be right for
Chronic Obstructive Pulmonary Disease (COPD)
AstraZeneca 990
Large-scale testing (Phase 3)Study completedNCT01854645
What this trial is testing

Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)

Who this might be right for
Chronic Obstructive Pulmonary Disease
Pearl Therapeutics, Inc. 2,103
Post-approval studies (Phase 4)Study completedNCT02417649
What this trial is testing

Advanced Immunological Approach in COPD Exacerbation

Who this might be right for
Chronic Obstructive Pulmonary Disease (COPD)
Lallemand Pharma AG 288
Large-scale testing (Phase 3)Study completedNCT05046795
What this trial is testing

Revefenacin in Chinese Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease(COPD)

Who this might be right for
COPD
Mylan Pharma UK Ltd. 258
Large-scale testing (Phase 3)Study completedNCT02347072
What this trial is testing

24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003, Open-Label Spiriva® Respimat® as an Active Control, and Placebo

Who this might be right for
COPD
Pearl Therapeutics, Inc. 80
Next Page

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation